Coronavirus: Study noted that it is safe to combine …

The people under 60 who received the first dose of vaccine with Astrazeneca then completed the diagram with a dose of Pfizer had a strong immune response and mild to moderate side effects, concluded a clinical study conducted in Spain.

The study CombiVacs, from the Carlos III Health Institute (ISCIII), was carried out in correlation with the decision taken by the Ministry of Health in early April to only vaccinate with AstraZeneca those over 60 years old, after the appearance of very rare thrombotics events, especially in people under this age. Due to this health decision, those under 60 who received a dose of AstraZeneca could not receive the second injection of the same specialty, a measure which mainly concerned essential personnel such as teachers and security forces.

The investigation established that the side effects of the combination of the two specialties are mild and very similar to those of vaccination with AstraZeneca. According to the results, the protection conferring a second injection of Pfizer it can be even higher, since the neutralizing antibodies, which protect the body against the coronavirus, are multiplied by seven, while in trials of two doses of the same drug, they were three times more.

“Today’s results support the possibility of vaccinating patients who received the first dose of AstraZeneca, but the decision does not correspond to the researchers of this study” but to the Spanish health authorities, said Jesús Antonio Frías, coordinator of the study. ISCIII Clinical Research Network.

How did the investigation go?

The trial was conducted in five spanish hospitals: La Paz and the San Carlos de Madrid Clinic, the Vall d’Hebron and the Barcelona Clinic, and the Cruces de Vizcaya, while the National Center for Microbiology participated as the study’s central analytical laboratory.

In the phase 2, controlled, randomized and adaptive clinical trial, 6 participated76 people between 18 and 59 years old from different age groups and regions of Spain who have received a single dose of AstraZeneca.

These people were divided into two groups: one, consisting of 226 people, received the dose “immediately”; the other, composed of 450, received it after 28 days. The results are those analyzed 14 days after receiving the dose of Pfizer.

According to the Spanish newspaper El País, the Ministry of Health waited for the conclusion of the study to decide how to proceed with it. 1.5 million essential workers children under 60 who have received a first dose of the Anglo-Swedish vaccine.

These people missed the second dose after April 7, when authorities decided to stop vaccination in people under the age of 60 due to drug-related effects, rare but life-threatening thrombi that were more common (although very rare) in young people. people.